This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 11221 results found since Jan 2013.
Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Series A financing co-led by Westlake Village BioPartners and Versant Ventures
Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms
Initial pipeline addressing myotoni... Regenerative Medicine, Venture Capital Kate Therapeutics, gene therapy, X-linked myotubular myopathy
Source: HSMN NewsFeed - June 8, 2023 Category: Pharmaceuticals Source Type: news
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM)
TOKYO and SAN DIEGO, June 8, 2023 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki ... Biopharmaceuticals, Regenerative Medicine, Licensing Astellas Pharma, Kate Therapeutics, X-linked myotubular myopathy, gene therapy
Source: HSMN NewsFeed - June 8, 2023 Category: Pharmaceuticals Source Type: news
The diagnostic value of serum YKL-40 for myocardial involvement in immune-mediated necrotising myopathy
CONCLUSIONS: YKL-40 could be a promising non-invasive biomarker for diagnosing myocardial involvement in IMNM. However, larger prospective study is warranted.PMID:37279143 | DOI:10.55563/clinexprheumatol/itrujk
Source: Clinical and Experimental Rheumatology - June 6, 2023 Category: Rheumatology Authors: Li Xu Meng-Ge Yang Shejing Hu Yue Li Bi-Tao Bu Suqiong Ji Source Type: research
Cardiovascular risk in myositis patients compared to the general population
CONCLUSION: Significantly higher prevalence of traditional risk factors and subclinical atherosclerosis was observed in IIM patients compared with HC.PMID:37279728 | DOI:10.1093/rheumatology/kead271
Source: Atherosclerosis - June 6, 2023 Category: Cardiology Authors: Sabina Oreska Hana Storkanova Jaroslav Kudlicka Vladimir Tuka Ondrej Mikes Zdislava Krupickova Martin Satny Eva Chytilova Jan Kvasnicka Maja Spiritovic Barbora Hermankova Petr Cesak Marian Rybar Karel Pavelka Ladislav Senolt Herman Mann Jiri Vencovsky Mic Source Type: research
The diagnostic value of serum YKL-40 for myocardial involvement in immune-mediated necrotising myopathy
CONCLUSIONS: YKL-40 could be a promising non-invasive biomarker for diagnosing myocardial involvement in IMNM. However, larger prospective study is warranted.PMID:37279143 | DOI:10.55563/clinexprheumatol/itrujk
Source: Clinical and Experimental Rheumatology - June 6, 2023 Category: Rheumatology Authors: Li Xu Meng-Ge Yang Shejing Hu Yue Li Bi-Tao Bu Suqiong Ji Source Type: research
